You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief

    SBC: VANISH THERAPEUTICS INC            Topic: NINDS

    Project Summary The lack of effective pain treatments has catalyzed the opioid epidemic in America, causing an estimated 93,000 deaths in 2020, calling for more effective and non-opioid based management. One alternative pain treatment is via nerve stimulators, which are devices placed near a peripheral nerve or on the spinal cord and use electrical signals to modulate the perception of pain. Most ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution

    SBC: Trevarx Biomedical, Inc.            Topic: 102

    ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Direct Air Capture by Ion-Exchange Sorbent and Low-Grade Heat

    SBC: ADVANCED COOLING TECHNOLOGIES INC            Topic: C5422a

    Anthropogenic CO2 emissions are widely accepted as the primary driver of global climate change, leading to many adverse outcomes for humanity. While CO2 emissions are equally distributed within the atmosphere, the negative impacts of human-induced climate change are not, with marginalized people suffering the worst. While renewable energy technologies can reduce future emissions, large-scale atmos ...

    STTR Phase II 2023 Department of Energy
  5. Rapid Chemical Vapor Threat Mapping with Cooperative Ground and UAS Sensors

    SBC: MESH INC            Topic: A10AT022

    A single, ground-based, passive, standoff chemical agent vapor sensor cannot map a chemical vapor cloud because passive sensors only measure direction and not range to vapor clouds. It is not always possible, especially for a ground vehicle mounted standoff sensor, to have additional ground-based sensors at favorable vantage points to assist in threat mapping. The objective of the proposed effort ...

    STTR Phase II 2023 Department of DefenseArmy
  6. SIRPant Technology for anti-Cancer Immunity

    SBC: SIRPANT IMMUNOTHERAPEUTICS INC            Topic: 102

    PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    ABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HS ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Engineered Printed Propulsion Technology: A Study on Geometry-Based Thermal Management

    SBC: PLUS DESIGNS INC            Topic: MDA21T005

    Tungsten-based materials such as pure tungsten and tungsten-rhenium alloys are attractive hot-walled material options for solid rocket motor components, but they possess a high thermal diffusivity and can present some design challenges for thermal management. These challenges manifest themselves where geometric constraints, such as small thicknesses/volumes, coupled with long burn times and high t ...

    STTR Phase II 2023 Department of DefenseMissile Defense Agency
  9. AI/ML Data Management Software System for NSRCs

    SBC: VISIMO LLC            Topic: C5315a

    C53-15a-271273Research labs are unable to effectively collaborate and fully utilize microscopy data due to data silos, insufficient data interoperability, and a lack of common data management standards. To address this problem, this innovation will increase the impact of scientific datasets by delivering (1) an extensible software system and (2) microscopy tools which support findability, accessib ...

    STTR Phase II 2023 Department of Energy
  10. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government